香雪製藥(300147.SZ)子公司擬與兩自然人共設香雪醫藥技術(北京)
格隆匯12月31日丨香雪製藥(300147.SZ)公佈,因經營發展需要,公司控股子公司北京香雪醫藥生物科技有限公司(“北京香雪”)與自然人成龍、張文娟共同簽署了《合資協議書》,三方將共同出資成立香雪醫藥技術(北京)有限公司(以工商部門核准登記的名稱為準,“合資公司”)。
香雪醫藥技術(北京)有限公司(暫定,以工商部門核准登記的名稱為準)經營範圍:技術開發、技術轉讓、技術諮詢、技術服務;醫學研究(不含診療活動);貨物進出口、技術進出口、代理進出口;銷售醫療器械I類。(暫定,最終以工商核准為準);註冊資本500萬元人民幣,其中北京香雪出資400萬元人民幣,持有合資公司80%股權。
近年來,國家大力支持鼓勵製藥企業開展仿製藥一致性評價,並全面試行藥品上市許可持有人制度(MAH),仿製藥替代原研的趨勢將在未來持續存在。北京香雪對外投資設立合資公司,將開展仿製藥評估、立項工作,未來將與國內外知名研發機構建立基於仿製藥品種項目的合作,通過合作研發、MAH持證、原料委託、製劑委託生產、產品自主銷售等業務,逐漸形成以呼吸、兒科消化、麻醉為主要特色的多產品運營,增強細分領域競爭力,拓展發展空間。此次對外投資設立合資公司的資金來源為北京香雪自籌資金,不會對公司財務狀況和經營成果產生不良影響,不存在損害上市公司及股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.